<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ralph Kupka, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12936951"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bipolar disorder is characterized by mood episodes that are nearly always recurrent [<a href="#rid1">1,2</a>]. Patients who experience at least four episodes during a 12-month period are classified as “rapid cycling” [<a href="#rid2">2</a>]. The term was first used in 1974 to describe bipolar patients who were unresponsive to <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid3">3</a>]. However, it is now clear that any pharmacotherapy is often less beneficial for rapid cycling patients than non-rapid cycling patients, and that lithium may be as effective as other drugs for rapid cycling [<a href="#rid4">4,5</a>].</p><p>This topic reviews the treatment of mania and hypomania in rapid cycling patients. The treatment of major depression in rapid cycling patients, and the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder are discussed separately, as is the diagnosis and general treatment of bipolar disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p></p><p class="headingAnchor" id="H81537125"><span class="h1">DEFINITION OF RAPID CYCLING BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]. The major subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode and at least one major depressive episode, but the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p>Rapid cycling specifies a particular course of illness that can occur in bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [<a href="#rid2">2</a>]. The diagnostic criteria for rapid cycling in DSM-5 are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>At least four mood episodes in the previous 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The episodes meet both the symptom and duration criteria for mania, hypomania, or major depression. Although the symptoms that occur as part of a rapid cycling pattern are no different from symptoms that occur as part of a non-rapid cycling pattern, rapid cycling episodes are typically of shorter duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The episodes are demarcated by a period of partial or full remission for at least two months, or by a switch to an episode of opposite polarity. Manic and hypomanic are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression.</p><p></p><p>In some patients, hypomanic/manic and depressive episodes alternate for relatively longer periods without an interval of remission (continuous cycling) [<a href="#rid6">6</a>].</p><p>Additional information about the clinical features and diagnosis of rapid cycling are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H86794887"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Mania and hypomania differ in that manic episodes are more severe and have a greater impact on psychosocial functioning  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>) [<a href="#rid2">2</a>]. Nevertheless, for the purpose of treatment, they are considered to be similar and thus treated with the same medications [<a href="#rid7">7-11</a>].</p><p>Treatment of manic and hypomanic episodes in patients with rapid cycling bipolar disorder is comparable to the treatment of mania or hypomania in non-rapid cycling patients [<a href="#rid7">7-11</a>]. Mania always necessitates pharmacotherapy. However, the severity of a hypomanic episode may be so limited that watchful waiting is an acceptable alternative to acute pharmacotherapy, especially for patients who are functioning well and have good social support and a history of good adherence to monitoring; in these cases, maintenance pharmacotherapy is emphasized. In addition, we suggest that clinicians discontinue antidepressants in patients with mania or hypomania.</p><p>Remission of individual rapid cycling mood episodes often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes, and clinicians should attempt to prescribe medications for acute mood episodes that are suitable for maintenance treatment.</p><p>Response to pharmacotherapy appears to be poorer in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [<a href="#rid6">6,12-14</a>]. A meta-analysis of nine studies (primarily observational, 1424 bipolar patients) examined improvement of mood episodes and rates of recurrence in rapid cycling and non-rapid cycling patients, and found that an inferior response to medications was more probable in rapid cycling patients (risk ratio 1.4, 95% CI 1.3-1.6) [<a href="#rid4">4</a>]. Clinicians may find that it is not feasible for rapid cycling patients to fully remit from a mood episode or avoid recurrences [<a href="#rid15">15</a>], and that a more realistic goal is to improve functioning and reduce the frequency, intensity, and duration of mood episodes [<a href="#rid4">4</a>]. The difficulties posed by rapid cycling usually necessitate referral to a psychiatrist.</p><p>The mood episodes that occur during rapid cycling are demarcated by a period of euthymia for at least two months, or by a switch from an episode of one polarity to an episode of the other polarity (eg, major depression to mania) without intervening euthymia [<a href="#rid8">8</a>]. Rapid cycling that is characterized by continuous switching between poles may respond more poorly to treatment than rapid cycling that includes intermittent periods of euthymia [<a href="#rid16">16,17</a>].</p><p>Poor adherence to pharmacotherapy occurs in 20 to 40 percent of rapid cycling bipolar patients [<a href="#rid18">18-20</a>], and appears to be more common in rapid cycling than non-rapid cycling patients [<a href="#rid21">21</a>]. Nonadherence in bipolar disorder is often managed with psychoeducation, but this has not been studied in rapid cycling patients. Adherence to treatment and use of psychoeducation in bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="headingAnchor" id="H2066405"><span class="h2">Monitoring the patient</span><span class="headingEndMark"> — </span>Rapid cycling bipolar patients should be monitored for therapeutic and adverse medication effects, with particular attention to suicidal ideation and psychosis. The frequency of monitoring is determined by the patient’s clinical status. Hospitalized patients are monitored daily. Outpatients are commonly seen on a weekly basis until they have responded (ie, the patient’s safety has stabilized and the number, intensity, and frequency of psychotic and mood symptoms has improved substantially). Following response, patients can be seen every two to four weeks until they remit. Although some clinicians suggest that patients or caregivers record daily symptoms in a mood diary to help judge the effectiveness of treatment [<a href="#rid22">22</a>], this is not standard practice.</p><p>For rapid cycling bipolar patients who remit and remain stable, monitoring can be tapered, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one to three more visits, then every month for one to three visits, and then every two months for one to three visits. Continuously stable patients can ultimately be seen every three to six months. More frequent visits should be scheduled for patients who develop symptoms or side effects.</p><p class="headingAnchor" id="H289533874"><span class="h2">Duration of treatment trial</span><span class="headingEndMark"> — </span>For rapid cycling bipolar patients, we suggest that clinicians try to prescribe a particular treatment regimen for at least two to four months before determining whether it effectively improves acute symptoms and reduces the frequency, intensity, and duration of recurrent mood episodes [<a href="#rid14">14,23</a>].</p><p class="headingAnchor" id="H6997118"><span class="h1">SEVERE EPISODES</span><span class="headingEndMark"> — </span>Severe mania is characterized by one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Suicidal ideation or behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Homicidal ideation or behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aggressive behavior.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychotic features (ie, delusions or hallucinations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor judgement that places the patient or others at imminent risk of being harmed (eg, disinhibited or impulsive behavior at work or at home). Severe mania may lead to job loss and the break-up of relationships.</p><p></p><p>Severely ill patients generally require hospitalization [<a href="#rid7">7-9</a>].</p><p>For rapid cycling bipolar patients with severe mania, we usually use a medication combination, which is consistent with the recommendation of treatment practice guidelines [<a href="#rid7">7-10</a>] and many authorities [<a href="#rid6">6,23</a>]. Selecting a medication combination for treatment of severe mania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Initial treatment'</a>.)</p><p>For rapid cycling bipolar patients with severe mania that does not respond to one medication combination, we suggest additional medication combination trials. Treatment of resistant patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Treatment-resistant patients'</a>.)</p><p>For rapid cycling bipolar patients with severe maniac episodes that do not respond to four to six medication combinations, we suggest electroconvulsive therapy (ECT). Treatment of refractory patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Treatment-refractory patients'</a>.)</p><p class="headingAnchor" id="H86794592"><span class="h1">MILD TO MODERATE EPISODES</span><span class="headingEndMark"> — </span>Mild to moderate illness is marked by the absence of suicidal or homicidal ideation or behavior, aggressiveness, psychotic features, and poor judgement that places the patient or others at imminent risk of being harmed. Nevertheless, the instability of mood and functioning in mild to moderate rapid cycling bipolar disorder is distressing to patients and caregivers. Monotherapy is commonly used for initial treatment of rapid cycling patients with hypomania or mild to moderate mania.</p><p class="headingAnchor" id="H86796256"><span class="h2">First line medications</span><span class="headingEndMark"> — </span>For rapid cycling patients with hypomanic or mild to moderate manic episodes, we suggest <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> monotherapy, based upon results from randomized trials for subgroups of rapid cycling patients [<a href="#rid24">24-26</a>], as well as results for bipolar patients in general [<a href="#rid27">27</a>]. We generally prefer risperidone and aripiprazole because they cause less weight gain [<a href="#rid28">28</a>]. Reasonable alternatives to risperidone, aripiprazole, or olanzapine include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, in order of preference. The doses, side effects, and pharmacology of these drugs are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Medication doses and side effects'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"</a>.)</p><p></p><p>For rapid cycling bipolar patients who do not respond to treatment with one first-line medication, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another first-line medication is started and titrated up. (Response is defined as stabilization of the patient’s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms). The failed medication is generally tapered by the same amount for each dose decrease. As an example, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> 4 mg per day is decreased by 1 to 2 mg per day, every one to two days.</p><p>For rapid cycling patients with hypomania or mild to moderate mania, evidence for the efficacy of <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> includes the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risperidone</strong> – A three-week randomized trial compared <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> (mean dose 4 mg per day) with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (mean dose 15 mg per day) in patients with a manic or mixed (major depression concurrent with mania) episode [<a href="#rid26">26</a>]. In the subgroup with rapid cycling (n = 149), symptoms improved by approximately 60 percent with each drug, with no significant difference between the two medications; this was consistent with the finding that improvement with each drug was comparable in non-rapid cycling patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aripiprazole</strong> – Two randomized trials, each lasting three weeks, compared <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> (15 or 30 mg per day) with placebo in patients with a manic or mixed episode [<a href="#rid29">29,30</a>]. A pooled analysis found that in the subgroup with rapid cycling (n = 103), remission occurred in significantly more patients who received aripiprazole than placebo (48 versus 22 percent) [<a href="#rid24">24</a>]. This was consistent with the finding that aripiprazole was superior in the total sample.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olanzapine</strong> – Two randomized trials (three and four weeks in duration) compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 20 mg per day) with placebo in patients with a manic or mixed episode [<a href="#rid31">31,32</a>]. A pooled analysis found that in the subgroup with rapid cycling (n = 90), response (improvement from baseline on the mania rating scale ≥ 50 percent) occurred in significantly more patients treated with olanzapine than placebo (75 versus 46 percent) [<a href="#rid25">25</a>]; this was consistent with the finding that olanzapine was superior in the total sample [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 20-month randomized trial compared <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (mean serum concentration 0.9 mmol/L) with divalproex (mean serum concentration 77 mcg/mL) in 60 rapid cycling bipolar patients, who were initially stabilized for four weeks with open-label lithium plus divalproex [<a href="#rid18">18</a>]. Relapse was comparable in patients who received lithium or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> monotherapy (56 versus 50 percent), as was discontinuation due to adverse side effects (16 versus 4 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A review of eight studies (primarily open label) found that in 273 rapid cycling bipolar patients who were treated with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> for a mean of 50 months, the course of illness improved in 48 percent [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pooled analysis of three observational studies found that in 172 rapid cycling bipolar patients who were treated with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, recurrent mood episodes did not occur in 34 percent [<a href="#rid33">33</a>]. In a separate pooled analysis of three observational studies with 90 rapid cycling patients who received lithium, the frequency, intensity, and duration of mood episodes decreased by 50 percent or more in 59 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong><strong> (divalproex)</strong> – A 47-week randomized trial compared divalproex (mean serum concentration 70 mcg/mL) with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 20 mg per day) in patients with a manic or mixed episode [<a href="#rid34">34</a>]. In the subgroup with rapid cycling (n = 144), improvement from baseline with each drug was comparable. This was consistent with the finding in the total sample that remission was comparable for divalproex and olanzapine [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quetiapine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective observational study of 16 rapid cycling bipolar patients who were treated with <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (target dose 150 to 200 mg per day, maximum 800 mg per day) for up to one year found that manic symptoms improved by at least 50 percent in eight of the patients [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective observational study of 5 rapid cycling bipolar patients who were treated with adjunctive <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (mean dose 720 mg per day) for a mean of four months found that the mean mania rating scale score decreased from baseline by approximately 60 percent [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbamazepine</strong> – A review of 3 studies (primarily open label) found that in 133 rapid cycling bipolar patients who were treated with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> for a mean of 17 months, the course of illness improved in 45 percent [<a href="#rid4">4</a>]. In addition, carbamazepine and <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> were comparably effective in studies that directly compared the two treatments.</p><p></p><p class="headingAnchor" id="H86796263"><span class="h2">Resistant patients</span><span class="headingEndMark"> — </span>Based upon clinical experience, rapid cycling patients with hypomania or mild to moderate mania often do not respond to treatment with two to three sequential monotherapy trials with first-line medications. For these resistant patients, we suggest combining <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> with a second-generation antipsychotic (except <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>), based upon meta-analyses of randomized trials that studied the general treatment of manic and mixed (major depression concurrent with mania) episodes [<a href="#rid38">38-40</a>]. Generally, every medication that has not clearly improved the course of illness over approximately three cycles of manic/hypomanic plus depressive episodes should be tapered and stopped to prevent the accumulation of multiple ineffective medications. The efficacy of medication combinations is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Initial treatment'</a>.)</p><p>We generally use a medication combination consisting of:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a> plus <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>; or</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> plus <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a></p><p></p><p>However, there is no high quality evidence of superior efficacy for any specific combination in treating rapid cycling patients with hypomania or mild to moderate mania. Reasonable alternatives to <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> include <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> or another first-generation antipsychotic, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>. Selecting a combination is guided by past response to medications, the past response of family members with bipolar disorder to medications, specific symptoms, side effect profiles, potential drug-drug interactions, comorbid general medical conditions, patient preference, and cost. Specific medication interactions that can occur may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>For resistant rapid cycling bipolar patients receiving <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> monotherapy for hypomanic or mild to moderate manic episodes, we add <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> to their regimen. For resistant patients receiving risperidone, aripiprazole, or olanzapine monotherapy, we add lithium or valproate to their regimen. The dose and side effects of lithium, valproate, risperidone, aripiprazole, and olanzapine are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Medication doses and side effects'</a>.)</p><p>Resistant rapid cycling bipolar patients who do not respond to or tolerate one medication combination should be treated with a second medication combination. Generally, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is switched to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> or vice versa. As an example, for patients who do not respond to lithium plus <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, we suggest tapering and discontinuing lithium at the same time that valproate is started and titrated up. Lithium is generally tapered over one to two weeks by the same amount for each dose decrease (eg, lithium 1500 mg per day is decreased by 300 to 600 mg per day, every one to two days).</p><p>Conversely, for resistant rapid cycling patients who do not respond to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> plus <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, we suggest tapering and discontinuing valproate at the same time that <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is started and titrated up. Valproate is generally tapered over one to two weeks by the same amount for each dose decrease (eg, valproate 2000 mg per day is decreased by 250 to 500 mg per day, every one to two days).</p><p>Although the antipsychotic (<a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>) is generally continued at the same dose when <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> is switched to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> or vice versa, it is also reasonable to switch the antipsychotic after lithium has been switched to valproate (or vice versa). The failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg, risperidone 4 mg per day is decreased by 1 to 2 mg per day, every one to two days), and at the same time, the new antipsychotic is started and titrated up.</p><p class="headingAnchor" id="H86796271"><span class="h2">Refractory patients</span><span class="headingEndMark"> — </span>Based upon clinical experience, rapid cycling bipolar patients with hypomania or mild to moderate mania generally respond to sequential pharmacotherapy trials. For refractory patients who do not respond to four to eight medication combinations involving <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> plus a second- or first-generation antipsychotic (not including <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>), we suggest, in order of preference, using clozapine as monotherapy or add-on therapy, administering electroconvulsive therapy, or adding high-dose <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> (T4).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clozapine</strong> – <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> as monotherapy or augmentation is an alternative to <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> for refractory rapid cycling bipolar patients with hypomania or mild to moderate mania [<a href="#rid41">41</a>]. We generally use clozapine as monotherapy if the existing medication regimen has provided little to no benefit or is poorly tolerated; clozapine is titrated up as the failed drugs are tapered and discontinued concurrently over one to two weeks. The failed drugs are usually decreased by the same amount for each dose decrease. The dose, side effects, and pharmacology of clozapine are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">"Schizophrenia in adults: Guidelines for prescribing clozapine"</a>.)</p><p></p><p class="bulletIndent1">For rapid cycling patients with refractory hypomanic or mild to moderate manic episodes, we generally use <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> as augmentation if the existing medications have provided modest to moderate benefit and is well tolerated, and maintain the existing drugs at the same doses. However, if clozapine is added to a regimen that includes another second-generation antipsychotic, the failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> 30 mg per day is decreased by 5 to 10 mg per day, every one to two days), and at the same time, clozapine is started and titrated up.</p><p></p><p class="bulletIndent1">Evidence for the efficacy of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> in treating refractory rapid cycling bipolar patients with hypomania or mild to moderate mania includes the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A one-year, open-label, randomized study compared <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> plus treatment as usual with treatment as usual in patients with treatment resistant bipolar disorder [<a href="#rid42">42</a>]; in the subgroup with rapid cycling (n = 15) who received adjunctive clozapine (mean dose 238 mg per day), more than 80 percent showed at least some improvement [<a href="#rid43">43</a>]. This was consistent with the finding that clozapine was beneficial in the total sample [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective observational study of 7 patients treated for 13 weeks with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> monotherapy (350 to 800 mg per day) found that mean scores on the mania rating scale decreased by more than 60 percent [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study identified 13 patients with rapid cycling bipolar disorder who received <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> (mean dose 180 mg/day, range 25 to 600 mg/day) as add-on therapy or monotherapy [<a href="#rid45">45</a>]. Outcomes during the year before clozapine treatment were compared with the year after clozapine was started. Clozapine was associated with fewer manic episodes, depressive episodes, hospitalizations, and suicide attempts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electroconvulsive therapy </strong>– Electroconvulsive therapy (ECT) appears to be effective for mania that occurs in the context of rapid cycling, based upon randomized trials that found ECT was efficacious for the general treatment of mania, as well as observational studies of ECT for rapid cycling patients [<a href="#rid46">46</a>]. In addition, ECT induced mania is rare, and there are no reports of ECT induced rapid cycling. The efficacy of ECT for the general treatment of mania is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Mania'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levothyroxine</strong><strong> (T4)</strong> – For refractory rapid cycling bipolar patients with hypomanic or mild to moderate manic episodes, we suggest high dose, supraphysiologic <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> (T4) added to ongoing pharmacotherapy, based upon limited evidence [<a href="#rid47">47-50</a>]. Prior to using T4, patients should be screened for contraindications such as hyperthyroidism, cardiac conditions, pregnancy and breastfeeding, osteoporosis in postmenopausal women, and dementia.</p><p></p><p class="bulletIndent1">The goal of treatment with supraphysiologic T4 doses is to increase serum free T4 concentrations by approximately 50 percent of baseline concentrations; the dose of T4 should result in free T4 concentrations that exceed upper reference values for normal and a low thyroid-stimulating hormone (TSH) (&lt;0.01 mU/L). In rapid cycling patients with a normal baseline TSH concentration, T4 is started at 50 mcg per day, as a single morning dose approximately 30 minutes before breakfast. The dose is increased by increments of 50 mcg per day every week, depending upon response and tolerability, until the target values for free T4 and TSH are achieved. The maximum dose is 400 mcg per day. In patients with subclinical or overt hypothyroidism, the dose should be started at 25 mcg per day and increased by 25 mcg per day every week, until the target values for free T4 and TSH are achieved. Monitoring of patients should include signs of hyperthyroidism. (See  <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p></p><p class="bulletIndent1">Limited evidence for the efficacy of adjunctive, high dose <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> includes the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One trial enrolled euthyroid patients (n = 23) with rapid cycling who had not responded to a course of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> plus other medications (eg, antidepressants, benzodiazepines, and/or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>), and randomly assigned them to add-on <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> or placebo; patients were followed for at least four months [<a href="#rid51">51</a>]. The dose of levothyroxine was titrated up until the free T4 index was between 4.5 and 7.5 mcg/dL or until TSH suppression was achieved (&lt;0.1 mcIU/mL). Improvement was superior with adjunctive levothyroxine than placebo, such that the total duration of euthymia was greater with levothyroxine, and the duration of mixed states was less with levothyroxine. Adverse effects with levothyroxine included mild tremor, hot flashes, and diaphoresis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional evidence for the efficacy of <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> includes open-label treatment of 27 rapid cycling bipolar patients (described in single-case reports and three case series) [<a href="#rid52">52</a>]. Levothyroxine was dosed between 50 to 500 mcg daily and given for 1 to 108 months. At least mild to moderate improvement occurred in 81 percent of the patients, and levothyroxine was usually well tolerated. In addition, there was generally no relationship between baseline thyroid status and response [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H1370242"><span class="h1">MAINTENANCE TREATMENT</span><span class="headingEndMark"> — </span>For rapid cycling bipolar patients with hypomania or mania that responds to acute pharmacotherapy, we recommend maintenance treatment and typically use the same regimen that achieved response. Evidence for the efficacy of maintenance treatment includes the following trials [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A 52-week, randomized maintenance trial compared <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> long-acting injectable (25 to 50 mg intramuscularly every two weeks) plus treatment as usual with placebo plus treatment as usual in 139 rapid cycling bipolar patients (who initially remitted with risperidone injectable plus treatment as usual) [<a href="#rid13">13,55</a>]. Relapse of a mood episode occurred in significantly fewer patients who received adjunctive risperidone than placebo (22 versus 48 percent). In addition, discontinuation due to adverse events was comparable for risperidone and placebo (4 and 2 percent of patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 100-week, randomized maintenance trial compared <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> (15 or 30 mg per day) with placebo in bipolar patients who were initially stabilized for at least six weeks with open-label aripiprazole [<a href="#rid56">56</a>]. In the subgroup with rapid cycling (n = 28), time to relapse was significantly longer with aripiprazole than placebo [<a href="#rid57">57</a>]; this was consistent with the finding that aripiprazole was superior in the total sample [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 48-week, randomized maintenance trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 20 mg per day) with placebo in bipolar patients who were initially stabilized for two weeks with open-label olanzapine [<a href="#rid58">58</a>]. In the subgroup with rapid cycling (n = 179), time to recurrence of a mood episode was significantly longer with olanzapine than placebo. This was consistent with the finding that olanzapine was superior in the total sample.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 104-week, randomized maintenance trial compared <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a> (mean dose 546 mg per day), <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (median serum concentration 0.63 mEq/L), and placebo in bipolar patients who were initially stabilized for four weeks with open-label quetiapine [<a href="#rid59">59</a>]. In the subgroup with rapid cycling (n = 163), time to recurrence of a mood episode was significantly longer with quetiapine than placebo. Although the difference between lithium and placebo in rapid cycling patients was not significant, neither was the difference between quetiapine and lithium. Both quetiapine and lithium were superior to placebo in the total sample.</p><p></p><p class="headingAnchor" id="H2005160941"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H13497225"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (See  <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>.)</p><p></p><p>These educational materials can be used as part of psychoeducational psychotherapy. (See  <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'</a>.) </p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=16847" target="_blank">website</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The Depression and Bipolar Support Alliance (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=16847" target="_blank">the website</a> or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=16847" target="_blank">the website</a> or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class="headingAnchor" id="H86795525"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 3</a>). (See <a class="local">'Definition of rapid cycling bipolar disorder'</a> above and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during the past 12 months. Although the symptoms that occur as part of a rapid cycling pattern are no different from symptoms that occur as part of a non-rapid cycling pattern, rapid cycling episodes are typically of shorter duration. Separate episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See <a class="local">'Definition of rapid cycling bipolar disorder'</a> above and  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whereas rapid cycling mania always necessitates pharmacotherapy, hypomanic episodes may be so mild that acute pharmacotherapy is not necessary. In addition, antidepressants are discontinued in patients with hypomania or mania. Remission of rapid cycling mood episodes often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For rapid cycling bipolar patients with severe mania, we suggest initial treatment with a medication combination rather than monotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Severe episodes'</a> above and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Initial treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For resistant rapid cycling bipolar patients with severe mania that does not respond to one medication combination, we suggest additional medication combination trials rather than electroconvulsive therapy (ECT) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Severe episodes'</a> above and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Treatment-resistant patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment refractory patients with severe mania that does not respond to four to six medication combinations, we suggest ECT rather than additional trials of medication combinations (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Severe episodes'</a> above and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Treatment-refractory patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For rapid cycling bipolar patients with hypomanic or mild to moderate manic episodes, we suggest initial treatment with <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> monotherapy, rather than other medications (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We prefer risperidone and aripiprazole because they cause less weight gain. Reasonable alternatives to risperidone, aripiprazole, or olanzapine include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> (see <a class="local">'First line medications'</a> above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For resistant rapid cycling bipolar patients with hypomania or mild to moderate mania that does not respond to treatment with two to three sequential monotherapy trials, we suggest combining <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> with <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> rather than additional monotherapy trials (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, reasonable alternatives include lithium or valproate plus <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>. (See <a class="local">'Resistant patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid cycling bipolar patients with hypomanic or mild to moderate manic episodes may not respond to treatment with four to eight medication combinations. Treatment options for these refractory patients include, in order of preference, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> as monotherapy or augmentation, electroconvulsive therapy, or adding high-dose <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>. (See <a class="local">'Refractory patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For rapid cycling bipolar patients with hypomania or mania that responds to acute pharmacotherapy, we recommend maintenance treatment rather than no treatment (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We typically use the same regimen that achieved response. (See <a class="local">'Maintenance treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li><a class="nounderline abstract_t">Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.</a></li><li><a class="nounderline abstract_t">Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.</a></li><li><a class="nounderline abstract_t">Bauer MS. Bipolar Disorder. Ann Intern Med 2022; 175:ITC97.</a></li><li><a class="nounderline abstract_t">Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. February 11, 2020. https://www.nice.org.uk/guidance/cg185 (Accessed on December 22, 2020).</li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.</a></li><li class="breakAll">Kupka RW, Frye MA. Diagnosis and treatment of rapid cycling bipolar disorder. In: Bipolar Disorder. A clinician’s guide to biological treatments, 2nd Ed, Yatham L, Kusumakar V (Eds), Brunner-Routledge, 2009.</li><li class="breakAll">Ketter TA, Wang PW. Management of rapid-cycling bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.331.</li><li><a class="nounderline abstract_t">Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 Suppl 11:22.</a></li><li><a class="nounderline abstract_t">Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.</a></li><li><a class="nounderline abstract_t">Maj M, Pirozzi R, Magliano L, Bartoli L. The prognostic significance of "switching" in patients with bipolar disorder: a 10-year prospective follow-up study. Am J Psychiatry 2002; 159:1711.</a></li><li><a class="nounderline abstract_t">Maj M, Pirozzi R, Formicola AM, Tortorella A. Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder. Am J Psychiatry 1999; 156:1421.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162:2152.</a></li><li><a class="nounderline abstract_t">Sajatovic M, Elhaj O, Youngstrom EA, et al. Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting. J Clin Psychopharmacol 2007; 27:412.</a></li><li><a class="nounderline abstract_t">Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113.</a></li><li><a class="nounderline abstract_t">Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010; 71:296.</a></li><li><a class="nounderline abstract_t">Schärer LO, Krienke UJ, Graf SM, et al. Validation of life-charts documented with the personal life-chart app - a self-monitoring tool for bipolar disorder. BMC Psychiatry 2015; 15:49.</a></li><li><a class="nounderline abstract_t">Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.</a></li><li><a class="nounderline abstract_t">Suppes T, Eudicone J, McQuade R, et al. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008; 107:145.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003; 23:370.</a></li><li><a class="nounderline abstract_t">Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006; 67:1747.</a></li><li><a class="nounderline abstract_t">Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.</a></li><li><a class="nounderline abstract_t">Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.</a></li><li><a class="nounderline abstract_t">Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160:1651.</a></li><li><a class="nounderline abstract_t">Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20:536.</a></li><li><a class="nounderline abstract_t">Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702.</a></li><li><a class="nounderline abstract_t">Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841.</a></li><li><a class="nounderline abstract_t">Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.</a></li><li><a class="nounderline abstract_t">Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160:1263.</a></li><li><a class="nounderline abstract_t">Suppes T, Brown E, Schuh LM, et al. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005; 89:69.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Kelley ME, Rosenquist KJ, et al. Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study. J Affect Disord 2008; 105:305.</a></li><li><a class="nounderline abstract_t">Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4:335.</a></li><li><a class="nounderline abstract_t">Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.</a></li><li><a class="nounderline abstract_t">Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115:12.</a></li><li><a class="nounderline abstract_t">Frye MA, Altshuler LL, Bitran JA. Clozapine in rapid cycling bipolar disorder. J Clin Psychopharmacol 1996; 16:87.</a></li><li><a class="nounderline abstract_t">Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164.</a></li><li><a class="nounderline abstract_t">Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6:329.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759.</a></li><li><a class="nounderline abstract_t">Kılınçel O, Kılınçel Ş, Gündüz C, et al. The Role of Clozapine as a Mood Regulator in the Treatment of Rapid Cycling Bipolar Affective Disorder. Turk Psikiyatri Derg 2019; 30:268.</a></li><li><a class="nounderline abstract_t">Medda P, Toni C, Perugi G. The mood-stabilizing effects of electroconvulsive therapy. J ECT 2014; 30:275.</a></li><li><a class="nounderline abstract_t">Bauer M, Berghöfer A, Bschor T, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002; 27:620.</a></li><li class="breakAll">Goldberg JF, Berk M. Rapid cycling bipolar disorder: Phenomenology and treatment. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.333.</li><li class="breakAll">Ketter TA, Miller S, Wang PW, Culver J. Treatment of acute bipolar depression. In: Advances in the Treatment of Bipolar Disorder, Ketter TA (Ed), American Psychiatric Publishing, Washington, DC 2015. p.17.</li><li class="breakAll">El-Mallakh RS. Bipolar (manic-depressive) disorders. In: Psychiatry, Fourth Edition, Tasman A, Kay J, Lieberman JA, First MB, Riba MB (Eds), Wiley Blackwell, Weat Sussex, UK 2015. Vol Volume 1, p.857.</li><li><a class="nounderline abstract_t">Walshaw PD, Gyulai L, Bauer M, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ). Bipolar Disord 2018; 20:594.</a></li><li><a class="nounderline abstract_t">Kupka RW. Treatment options for rapid cycling bipolar disorder. Clinical Approaches in Bipolar Disorders 2006; 5:22.</a></li><li><a class="nounderline abstract_t">Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47:435.</a></li><li><a class="nounderline abstract_t">Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord 2013; 15:115.</a></li><li><a class="nounderline abstract_t">Macfadden W, Haskins T, Kujawa M, et al. Adjunctive risperidone long-acting injectable is effective in delaying relapse to a mood episode in patients with frequently relapsing bipolar disorder (abstract 584). Biol Psychiatry 2008; 63 (suppl):186S.</a></li><li><a class="nounderline abstract_t">Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68:1480.</a></li><li><a class="nounderline abstract_t">Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract 2008; 62:679.</a></li><li><a class="nounderline abstract_t">Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247.</a></li><li><a class="nounderline abstract_t">Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452.</a></li></ol></div><div id="topicVersionRevision">Topic 16847 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4589148" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical factors in lithium carbonate prophylaxis failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807371" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rapid-cycling bipolar disorder: effects of long-term treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816713" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bipolar Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199234" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rapid cycling bipolar disorder--diagnostic concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17029493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of rapid-cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18198271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359677" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The prognostic significance of "switching" in patients with bipolar disorder: a 10-year prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484955" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263857" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632236" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192457" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20331931" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25885225" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Validation of life-charts documented with the personal life-chart app - a self-monitoring tool for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984894" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rapid cycling bipolar disorder: clinical characteristics and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17904226" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12920413" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Olanzapine versus placebo in acute mania: treatment responses in subgroups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17196055" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21851976" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20838345" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cardiovascular aspects of antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12944341" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16401666" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10327902" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986547" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14728111" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832240" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253344" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550787" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479667" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Quetiapine in the treatment of rapid cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16669715" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201861" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834431" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clozapine in rapid cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450255" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15225152" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Response to clozapine of rapid cycling versus non-cycling patients with a history of mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633686" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clozapine for treatment-refractory mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32594488" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Role of Clozapine as a Mood Regulator in the Treatment of Rapid Cycling Bipolar Affective Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010031" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The mood-stabilizing effects of electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377398" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377398" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377398" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377398" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29869405" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment options for rapid cycling bipolar disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184796" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437958" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A systematic review of the evidence on the treatment of rapid cycling bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adjunctive risperidone long-acting injectable is effective in delaying relapse to a mood episode in patients with frequently relapsing bipolar disorder (abstract 584)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960961" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373615" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449478" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22054050" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
